Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:STML

Stemline Therapeutics (STML) Stock Price, News & Analysis

Stemline Therapeutics logo

About Stemline Therapeutics Stock (NASDAQ:STML)

Advanced Chart

Key Stats

Today's Range
$11.83
$11.83
50-Day Range
$11.83
$11.83
52-Week Range
$3.21
$18.22
Volume
1,084 shs
Average Volume
1.52 million shs
Market Capitalization
$621.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive STML Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stemline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

STML Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
Trade These 7 Stocks Under $10 for Huge Profits
See More Headlines

STML Stock Analysis - Frequently Asked Questions

Stemline Therapeutics Inc (NASDAQ:STML) released its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.08. The biopharmaceutical company earned $13.33 million during the quarter, compared to the consensus estimate of $13.40 million. Stemline Therapeutics had a negative net margin of 150.30% and a negative trailing twelve-month return on equity of 48.14%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stemline Therapeutics investors own include TG Therapeutics (TGTX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), Sorrento Therapeutics (SRNE) and ZIOPHARM Oncology (ZIOP).

Company Calendar

Last Earnings
11/07/2019
Today
8/29/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:STML
CIK
1264587
Fax
N/A
Employees
92
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$76.82 million
Net Margins
-150.30%
Pretax Margin
N/A
Return on Equity
-48.14%
Return on Assets
-41.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.43
Quick Ratio
7.37

Sales & Book Value

Annual Sales
$43.22 million
Price / Sales
14.37
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.26 per share
Price / Book
3.63

Miscellaneous

Outstanding Shares
52,511,000
Free Float
N/A
Market Cap
$621.21 million
Optionable
Optionable
Beta
1.78
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:STML) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners